JILLIAN OAKLEAF: Open Payments
NPI 1477904050 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,214 in 154 payments from 24 companies in 2025. Trend: 2023 $3,067 · 2024 $3,724 · 2025 $4,214
Food & beverage: $3,967Education: $247
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 32 | $1,000 |
| Dendreon Pharmaceuticals LLC | 14 | $641 |
| Sumitomo Pharma America, Inc. | 20 | $400 |
| PFIZER INC. | 15 | $361 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $231 |
| Merck Sharp & Dohme LLC | 9 | $220 |
| Novartis Pharmaceuticals Corporation | 8 | $213 |
| Astellas Pharma US Inc | 2 | $162 |
| AstraZeneca Pharmaceuticals LP | 4 | $120 |
| UROGEN PHARMA, INC. | 5 | $105 |
Products named: ERLEADA, PROVENGE, XTANDI, LYNPARZA, Nubeqa, GEMTESA, PLUVICTO, ORGOVYX.
Industry payments across OK — which companies pay providers there.
